Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction

References

• Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, et al. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity. 2016;45(2):389–16. doi: 10.1016/j.immuni.2016.07.011.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi: 10.1038/nri3862.
   PubMed Web of Science ®Google Scholar
• Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C. et al. T-Cell exhaustion signatures vary with tumor type and are severe in Glioblastoma. Clin Cancer Res. 2018;24(17):4175–4186. doi: 10.1158/1078-0432.CCR-17-1846.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Palova-Jelinkova L, Klapp V, Holicek P, Lanickova T, Kasikova L, Drozenova J, Cibula D, Álvarez-Abril B, García-Martínez E, Spisek R. et al. Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends Cancer. 2022;8(5):426–444. doi: 10.1016/j.trecan.2022.01.010.
   PubMed Web of Science ®Google Scholar
• Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G. Ovarian cancer Immunotherapy: turning up the heat. IJMS. 2019;20(12):2927. doi: 10.3390/ijms20122927.
   Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218. doi: 10.1038/s41573-018-0007-y.
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev. 2011;30(1):141–151. doi: 10.1007/s10555-011-9289-9.
   PubMed Web of Science ®Google Scholar
• Sun J, Yan C, Xu D, Zhang Z, Li K, Li X, Zhou M, Hao D. Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy. Br J Cancer. 2022;126(11):1570–1580. doi: 10.1038/s41416-021-01692-4.
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402. doi: 10.1056/NEJMoa1910962.
   PubMed Web of Science ®Google Scholar
• Weimer P, Wellbrock J, Sturmheit T, Oliveira-Ferrer L, Ding Y, Menzel S, Witt M, Hell L, Schmalfeldt B, Bokemeyer C, et al. Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T cells in ovarian cancer. Cells. 2022;11(6):964. doi: 10.3390/cells11060964.
   PubMed Web of Science ®Google Scholar
• Brauneck F, Haag F, Woost R, Wildner N, Tolosa E, Rissiek A, Vohwinkel G, Wellbrock J, Bokemeyer C, Schulze zur Wiesch J, et al. Increased frequency of TIGIT(+)CD73-CD8(+) T cells with a TOX(+) TCF-1low profile in patients with newly diagnosed and relapsed AML. Oncoimmunology. 2021;10(1):1930391. doi: 10.1080/2162402X.2021.1930391.
   PubMed Web of Science ®Google Scholar
• Jantz-Naeem N, Böttcher-Loschinski R, Borucki K, Mitchell-Flack M, Böttcher M, Schraven B, Mougiakakos D, Kahlfuss S. TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment. Front Oncol. 2023;13:1060112. doi: 10.3389/fonc.2023.1060112.
   PubMed Web of Science ®Google Scholar
• Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173–185. doi: 10.1038/s41577-019-0224-6.
   PubMed Web of Science ®Google Scholar
• Dumitru A, Dobrica EC, Croitoru A, Cretoiu SM, Gaspar BS. Focus on PD-1/PD-L1 as a therapeutic target in ovarian cancer. IJMS. 2022;23(20):12067. doi: 10.3390/ijms232012067.
   Google Scholar
• Shevchenko I, Mathes A, Groth C, Karakhanova S, Müller V, Utikal J, Werner J, Bazhin AV, Umansky V. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. Oncoimmunology. 2020;9(1):1744946. doi: 10.1080/2162402X.2020.1744946.
   PubMed Web of Science ®Google Scholar
• Canale FP, Ramello MC, Núñez N, Furlan CLA, Bossio SN, Serrán MG, Boari JT, Del Castillo A, Ledesma M, Sedlik C. et al. CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells. Cancer Res. 2018;78(1):115–128. doi: 10.1158/0008-5472.CAN-16-2684.
   PubMed Web of Science ®Google Scholar
• Allard B, Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17(10):611–629. doi: 10.1038/s41571-020-0382-2.
   PubMed Web of Science ®Google Scholar
• Vigano S, Alatzoglou D, Irving M, Ménétrier-Caux C, Caux C, Romero P, Coukos G. Targeting adenosine in cancer immunotherapy to enhance T-Cell function. Front Immunol. 2019;10(925). doi: 10.3389/fimmu.2019.00925.
   PubMedGoogle Scholar
• Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DMA, Haibe-Kains B, Karn T. et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 2015;75(21):4494–4503. doi: 10.1158/0008-5472.CAN-14-3569.
   PubMed Web of Science ®Google Scholar
• Saraiva DP, Azeredo-Lopes S, Antunes A, Salvador R, Borralho P, Assis B, Pereira IL, Seabra Z, Negreiros I, Jacinto A. et al. Expression of HLA-DR in cytotoxic T lymphocytes: a validated predictive biomarker and a potential therapeutic strategy in breast cancer. Cancers Basel. 2021;13(15):3841. doi: 10.3390/cancers13153841.
   PubMed Web of Science ®Google Scholar
• Chen PY, Wu CY, Fang JH, Chen HC, Feng LY, Huang CY, Wei KC, Fang JY, Lin CY. Functional change of effector tumor-infiltrating CCR5(+)CD38(+)HLA-DR(+)CD8(+) T cells in glioma microenvironment. Front Immunol. 2019;10:2395. doi: 10.3389/fimmu.2019.02395.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Lichtenberger C, Steger G, Tillinger W, Scheiner O, Gangl A, Maurer D, Willheim M. Donor dependent, interferon-gamma induced HLA-DR expression on human neutrophils in vivo. Clin Exp Immunol. 2003;133(3):476–484. doi: 10.1046/j.1365-2249.2003.02245.x.
   PubMed Web of Science ®Google Scholar
• Mann TH, Kaech SM. Tick-TOX, it’s time for T cell exhaustion. Nat Immunol. 2019;20(9):1092–1094. doi: 10.1038/s41590-019-0478-y.
   PubMed Web of Science ®Google Scholar
• Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571(7764):270–274. doi: 10.1038/s41586-019-1324-y.
   PubMed Web of Science ®Google Scholar
• Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571(7764):211–218. doi: 10.1038/s41586-019-1325-x.
   PubMed Web of Science ®Google Scholar
• Wieland D, Kemming J, Schuch A, Emmerich F, Knolle P, Neumann-Haefelin C, Held W, Zehn D, Hofmann M, Thimme R. TCF1(+) hepatitis C virus-specific CD8(+) T cells are maintained after cessation of chronic antigen stimulation. Nat Commun. 2017;8(1):15050. doi: 10.1038/ncomms15050.
   PubMed Web of Science ®Google Scholar
• Kratchmarov R, Magun AM, Reiner SL. TCF1 expression marks self-renewing human CD8(+) T cells. Blood Adv. 2018;2(14):1685–1690. doi: 10.1182/bloodadvances.2018016279.
   PubMed Web of Science ®Google Scholar
• Brauneck F, Oliveira-Ferrer L, Muschhammer J, Sturmheit T, Ackermann C, Haag F, Schulze zur Wiesch J, Ding Y, Qi M, Hell L. et al. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro. Front Immunol. 2023;14:1250258. doi: 10.3389/fimmu.2023.1250258.
   PubMed Web of Science ®Google Scholar
• Prieske K, Alawi M, Jaeger A, Wankner MC, Eylmann K, Reuter S, Lebok P, Burandt E, Blessin NC, Schmalfeldt B. et al. Transcriptome analysis in vulvar squamous cell cancer. Cancers Basel. 2021;13(24):6372. doi: 10.3390/cancers13246372.
   PubMed Web of Science ®Google Scholar
• Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–2120. doi: 10.1093/bioinformatics/btu170.
   PubMed Web of Science ®Google Scholar
• Lieber S, Reinartz S, Raifer H, Finkernagel F, Dreyer T, Brogner H, Jansen JM, Wagner U, Worzfeld T, Müller R, et al. Prognosis of ovarian cancer is associated with effector memory CD8(+) T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells. Oncoimmunology. 2018;7(5):e1424672. doi: 10.1080/2162402X.2018.1424672.
   PubMed Web of Science ®Google Scholar
• Osuna-Gómez R, Arqueros C, Galano C, Mulet M, Zamora C, Barnadas A, Vidal S. Effector mechanisms of CD8+ HLA-DR+ T cells in breast cancer patients who respond to neoadjuvant chemotherapy. Cancers Basel. 2021;13(24):6167. doi: 10.3390/cancers13246167.
   PubMed Web of Science ®Google Scholar
• Tayama S, Motohara T, Narantuya D, Li C, Fujimoto K, Sakaguchi I, Tashiro H, Saya H, Nagano O, Katabuchi H. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. Oncotarget. 2017;8(27):44312–44325. doi: 10.18632/oncotarget.17871.
   PubMedGoogle Scholar
• Pei X, Zhu J, Yang R, Tan Z, An M, Shi J, Lubmann DM. Correction: CD90 and CD24 Co-Expression Is Associated with pancreatic intraepithelial neoplasias. PloS One. 2017;12:e0176804. doi:10.1371/journal.pone.0176804.
   PubMedGoogle Scholar
• Panagiotou E, Syrigos NK, Charpidou A, Kotteas E, Vathiotis IA. CD24: a novel target for cancer immunotherapy. JPM. 2022;12(8):1235. doi: 10.3390/jpm12081235.
   Google Scholar
• Zhang Y, Cui Q, Xu M, Liu D, Yao S, Chen M. Current advances in PD-1/PD-L1 blockade in Recurrent Epithelial ovarian cancer. Front Immunol. 2022;13:901772. doi: 10.3389/fimmu.2022.901772.
   PubMed Web of Science ®Google Scholar
• Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, Van De Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the Host Immune Response, TILs in invasive breast carcinoma and ductal carcinoma in situ. Metastatic Tumor Deposits And Areas For Further Research. Adv Anat Pathol. 2017;24(5):235–251.
   PubMed Web of Science ®Google Scholar
• Rådestad E, Klynning C, Stikvoort A, Mogensen O, Nava S, Magalhaes I, Uhlin M. Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. Oncoimmunology. 2019;8(2):e1535730. doi: 10.1080/2162402X.2018.1535730.
   PubMed Web of Science ®Google Scholar
• Sharma A, Schmidt-Wolf IGH. Tempering of exhausted T cells to comprehend their adaptive response for suitable clinical translation. Cell Mol Immunol. 2023;20(12):1401–1402. doi: 10.1038/s41423-023-01031-y.
   PubMed Web of Science ®Google Scholar
• Kim HD, Song GW, Park S, Jung MK, Kim MH, Kang HJ, Yoo C, Yi K, Kim KH, Eo S, Moon DB et al. Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma. Gastroenterology. 2018;155(6):1936–1950.e17. doi: 10.1053/j.gastro.2018.08.030.
   PubMed Web of Science ®Google Scholar
• Ma J, Zheng B, Goswami S, Meng L, Zhang D, Cao C, Li T, Zhu F, Ma L, Zhang Z, Zhang S. PD1(Hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer. 2019;7(1):331. doi: 10.1186/s40425-019-0814-7.
   PubMed Web of Science ®Google Scholar
• Chatani PD, Lowery FJ, Parikh NB, Hitscherich KJ, Yossef R, Hill V, Gartner JJ, Paria B, Florentin M, Ray S, Bera A. Cell surface marker-based capture of neoantigen-reactive CD8 + T-cell receptors from metastatic tumor digests. J Immunother Cancer. 2023;11(5):e006264. doi: 10.1136/jitc-2022-006264.
   PubMed Web of Science ®Google Scholar
• Thelen M, Lechner A, Wennhold K, von Bergwelt-Baildon M, Schlößer HA. CD39 expression defines cell exhaustion in tumor-infiltrating CD8(+) T Cells-Letter. Cancer Res. 2018;78(17):5173–5174. doi: 10.1158/0008-5472.CAN-18-0873.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Becht E, Fehlings M, Loh CY, Koo S-L, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557(7706):575–579. doi: 10.1038/s41586-018-0130-2.
   PubMed Web of Science ®Google Scholar
• Palomero J, Panisello C, Lozano-Rabella M, Tirtakasuma R, Díaz-Gómez J, Grases D, Pasamar H, Arregui L, Dorca Duch E, Guerra Fernández E. et al. Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer. J Immunother Cancer. 2022;10(12):e005443. doi: 10.1136/jitc-2022-005443.
   PubMed Web of Science ®Google Scholar
• Laumont CM, Wouters MCA, Smazynski J, Gierc NS, Chavez EA, Chong LC, Thornton S, Milne K, Webb JR, Steidl C. et al. Single-cell profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in ovarian cancer. Clin Cancer Res. 2021;27(14):4089–4100. doi: 10.1158/1078-0432.CCR-20-4394.
   PubMed Web of Science ®Google Scholar
• Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT, von Hoesslin M, Cullen JG, Fan Y. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019;571(7764):265–269. doi: 10.1038/s41586-019-1326-9.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu J, Li Y, Xiao M, Wang H, Tian Q, Li Z, Tang J, Hu L, Tan Y. et al. The Transcription Factor TCF1 Preserves the Effector Function of Exhausted CD8 T cells during chronic viral infection. Front Immunol. 2019;10:169. doi: 10.3389/fimmu.2019.00169.
   PubMed Web of Science ®Google Scholar
• Kim K, Park S, Park SY, Kim G, Park SM, Cho J-W, Kim DH, Park YM, Koh YW, Kim HR. et al. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer. Genome Med. 2020;12(1):22. doi: 10.1186/s13073-020-00722-9.
   PubMed Web of Science ®Google Scholar
• Tarhriz V, Bandehpour M, Dastmalchi S, Ouladsahebmadarek E, Zarredar H, Eyvazi S. Overview of CD24 as a new molecular marker in ovarian cancer. J Cell Physiol. 2019;234(3):2134–2142. doi: 10.1002/jcp.27581.
   PubMed Web of Science ®Google Scholar
• Kuerti S, Oliveira-Ferrer L, Milde-Langosch K, Schmalfeldt B, Legler K, Woelber L, Prieske K, Mahner S, Trillsch F. VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients. Oncotarget. 2017;8(26):43218–43227. doi: 10.18632/oncotarget.17978.
   PubMedGoogle Scholar
• Trillsch F, Kuerti S, Eulenburg C, Burandt E, Woelber L, Prieske K, Eylmann K, Oliveira-Ferrer L, Milde-Langosch K, Mahner S. et al. E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. Br J Cancer. 2016;114(2):213–220. doi: 10.1038/bjc.2015.436.
   PubMed Web of Science ®Google Scholar
• Volk A, Legler K, Hamester F, Kuerti S, Eylmann K, Rossberg M, Schmalfeldt B, Oliveira-Ferrer L. Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer. J Cancer Res Clin Oncol. 2023;149(17):15957–15967. doi: 10.1007/s00432-023-05354-1.
   PubMed Web of Science ®Google Scholar
• Oliveira-Ferrer L, Goswami R, Galatenko V, Ding Y, Eylmann K, Legler K, Kürti S, Schmalfeldt B, Milde-Langosch K. Prognostic impact of CEACAM1 in Node-Negative ovarian cancer Patients. Dis Markers. 2018;2018:1–10. doi: 10.1155/2018/6714287.
   Web of Science ®Google Scholar
• Bareche Y, Pommey S, Carneiro M, Buisseret L, Cousineau I, Thebault P, Chrobak P, Communal L, Allard D, Robson SC. et al. High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer. J Immunother Cancer. 2021;9(3):e001965. doi: 10.1136/jitc-2020-001965.
   PubMed Web of Science ®Google Scholar
• Raczkowski F, Rissiek A, Ricklefs I, Heiss K, Schumacher V, Wundenberg K, Haag F, Koch-Nolte F, Tolosa E, Mittrücker H-W. et al. CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to listeria monocytogenes. PloS One. 2018;13(5):e0197151. doi: 10.1371/journal.pone.0197151.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang H, Chen L, Feng Z, Gao L, Li Q. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and tim-3 in adult B lineage acute lymphoblastic leukemia. Cell Immunol. 2019;344:103958. doi: 10.1016/j.cellimm.2019.103958.
   PubMed Web of Science ®Google Scholar
• Kong Y, Jia B, Zhao C, Claxton DF, Sharma A, Annageldiyev C, Fotos JS, Zeng H, Paulson RF, Prabhu KS. et al. Downregulation of CD73 associates with T cell exhaustion in AML patients. J Hematol Oncol. 2019;12(1):40. doi: 10.1186/s13045-019-0728-3.
   PubMedGoogle Scholar
• Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Déjou C, Jecko D, Becquart O. et al. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 2019;27(8):2411–2425.e9. doi: 10.1016/j.celrep.2019.04.091.
   PubMed Web of Science ®Google Scholar
• Häusler SF, Del Barrio IM, Diessner J, Stein RG, Strohschein J, Hönig A, Dietl J, Wischhusen J. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res. 2014;6(2):129–139.
   PubMed Web of Science ®Google Scholar
• Brauneck F, Seubert E, Wellbrock J, Schulze zur Wiesch J, Duan Y, Magnus T, Bokemeyer C, Koch-Nolte F, Menzel S, Fiedler W. et al. Combined blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. Int J Mol Sci. 2021;22(23):12919. doi: 10.3390/ijms222312919.
   PubMed Web of Science ®Google Scholar
• Stamm H, Klingler F, Grossjohann E-M, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E. et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene. 2018;37(39):5269–5280. doi: 10.1038/s41388-018-0288-y.
   PubMed Web of Science ®Google Scholar
• Stamm H, Oliveira-Ferrer L, Grossjohann E-M, Muschhammer J, Thaden V, Brauneck F, Kischel R, Müller V, Bokemeyer C, Fiedler W. Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. OncoImmunology. 2019;8(12):e1674605. doi: 10.1080/2162402X.2019.1674605.
   PubMed Web of Science ®Google Scholar